479 related articles for article (PubMed ID: 17555945)
1. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
Carrillo-Muñoz AJ; Giusiano G; Guarro J; Quindós G; Guardia C; del Valle O; Rodríguez V; Estivill D; Cárdenes CD
Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
[TBL] [Abstract][Full Text] [Related]
2. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
[TBL] [Abstract][Full Text] [Related]
5. [In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis].
Carrillo-Muñoz AJ; Cárdenes CD; Carrillo-Orive B; Rodríguez V; Del Valle O; Casals JB; Ezkurra PA; Quindós G
Rev Iberoam Micol; 2005 Jun; 22(2):110-3. PubMed ID: 16107170
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial.
Ghannoum M; Isham N; Sheehan D
J Clin Microbiol; 2006 Jul; 44(7):2579-80. PubMed ID: 16825385
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
Sancak B; Alp S; Hasçelik G; Arikan S
Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
Sarifakioglu E; Seçkin D; Demirbilek M; Can F
Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activities of azole agents against the Malassezia species.
Miranda KC; de Araujo CR; Costa CR; Passos XS; de Fátima Lisboa Fernandes O; do Rosário Rodrigues Silva M
Int J Antimicrob Agents; 2007 Mar; 29(3):281-4. PubMed ID: 17223320
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility.
Carrillo-Muñoz AJ; Fernández-Torres B; Cárdenes DC; Guarro J
Chemotherapy; 2003 Sep; 49(5):248-51. PubMed ID: 14504436
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
14. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
15. [Is amphotericin B active against dermatophytes and Scopulariopsis brevicaulis?].
Carrillo-Muñoz AJ; Santos P; del Valle O; Casals JB; Quindós G
Rev Esp Quimioter; 2004 Sep; 17(3):244-9. PubMed ID: 15619653
[TBL] [Abstract][Full Text] [Related]
16. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
Diekema DJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Kroeger J; Jones RN; Pfaller MA
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):233-6. PubMed ID: 19070452
[TBL] [Abstract][Full Text] [Related]
17. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
18. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
19. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
20. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
